Navigation Links
ExonHit Therapeutics - 2007 Financial Results
Date:3/5/2008

nt to EUR 5.4 million, a decrease of 5% compared to the EUR 5.6 million achieved in 2006. At constant exchange rate, total revenues would have increased 4% between 2006 and 2007. 89% of ExonHit's 2007 revenues come from the Allergan collaboration; this compares with 76% in 2006. While revenues generated by the Therapeutics and SpliceArray(TM) activities posted double-digit growth in 2007, revenues form the bioMerieux collaboration decreased due to, on the one hand, the delays experienced in the recruitment of samples in prostate cancer and, on the other hand, the milestone achieved in 2006 in this collaboration.

R&D revenues from grants increased from EUR 0.01 million in 2006 to EUR 0.05 million in 2007.

R&D expenses have increased by 27% to EUR 8.6 million in 2007 when compared to EUR 6.8 million in 2006, mainly as a result of increased expenses in clinical trials. In 2007, R&D revenues covered 62% of the company's R&D expenses, as opposed to 83% in 2006.

Marketing and selling expenses have increased by 31% to EUR 1.0 million in 2007, compared to EUR 0.8 million in 2006. This increase mainly comes from the recruitment of new employees in this department and the increase in the selling and marketing effort for SpliceArray(TM).

General and administrative costs increased by 16% to EUR 3.5 million in 2007, compared to EUR 3.0 million in 2006. This increase mainly comes from the substantial increase of study and consultancy fees between the two years as a result of increased expenses to value our IP.

Operating expenses have been increased by 24% to EUR 13.2 million in 2007 compared to EUR 10.6 million in 2006. In 2007, 65% of these expenses are allocated to R&D compared to 64% in 2006.

Consequently, the company posted an operating loss of EUR 7.8 million in 2007, compared to EUR 5.0 million in 2006.

The presence of convertible bonds throughout fiscal year 2007, as well as the leasing of some pieces of equipment, explains
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
4. ExonHit and bioMerieux Amend Their Strategic Partnership
5. ExonHit Builds A New Organisation
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)...  Turing Pharmaceuticals AG announced that life sciences executive ... MSc,  has joined the company as president of ... holds a medical degree as well as a ... accomplishments in the pharmaceutical industry, and extensive clinical ... played a leadership role in numerous programs for ...
(Date:6/1/2015)... and RARITAN, N.J. , ... LLC (Janssen) announced data from the Phase 3 ... in progression-free survival (PFS) with trabectedin (YONDELIS ® ... liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with ... regimen. SAR3007 is the largest randomized Phase 3 ...
(Date:6/1/2015)... 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") ... 2015.  Biorem,s complete 2015 first quarter financial statements and MD&A have ... ended March 31,(in CDN$,000 except per share data) , ... , 1,974 Gross profit , 1,531 , ... (loss) , 528 , (531) Basic earnings (loss) ...
(Date:6/1/2015)... , June 1, 2015  The Val Skinner ... national innovative science curriculum for high school students focused ... 16 th annual LIFE Event (LPGA Pros in ... Ridge Country Club in West Caldwell, N.J. ... LPGA,s biggest stars raised more than $500,000 on Monday, ...
Breaking Biology Technology:Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3Val Skinner Foundation Announces Partnership With Discovery Education 2
... England, April 21 Paul Capital,Healthcare and Vernalis ... a financing agreement relating to frovatriptan, Vernalis, product,for ... will receive,approximately euro 18.4 million in cash from ... will receive approximately 90 per cent,of Menarini,s payments ...
... MIT Lincoln Laboratory have developed a powerful sensor ... and smallpox in less than three minutes. , ... for THreatening Environmental Releases), represents a significant advance ... Lincoln Lab,s Biosensor and Molecular Technologies Group. Current ...
... b3c newswire /   -  DuoCort AB announced ... Optimized Care for Adrenal Insufficiency – at the 10th ... Congress Centrum in Berlin.  The symposium will be held ... delegates attending ECE 2008 are invited to the symposium. ...
Cached Biology Technology:Vernalis and Paul Capital Healthcare Sign euro 18.4 Million Financing Agreement 2Vernalis and Paul Capital Healthcare Sign euro 18.4 Million Financing Agreement 3MIT's PANTHER sensor quickly detects pathogens 2DuoCort Hosts Adrenal Insufficiency Symposium at the 10th European Congress of Endocrinology in Berlin 2
(Date:5/7/2015)... 7, 2015 Fingerprint Cards ... and FPC1035, FPC,s smallest touch fingerprint sensors to ... considered for integration on the backside of the ... increased possibilities to integrate touch fingerprint sensors in ... improves possibilities for module manufacturers to customize the ...
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... the cells of blood vessels running through ovarian tumors. ... diagnosis and treatment for this disease. , The team ... Pennsylvania, and universities in Greece and Italy, used a ... ovarian tumors and four normal ovarian tissue samples. From ...
... markedly in their response to sleep deprivation, but the ... identify. Researchers have now found that a genetic difference ... particularly sensitive to the effects of sleep deprivation. The ... at the University of Surrey's Sleep Research Center, appear ...
... machine of their design, Duke University Medical Center researchers ... improve the ability of physicians to repair damaged joints ... experiments are successful, the scaffold could be used in ... Moutos, a graduate student in the Orthopedic Bioengineering Laboratory ...
Cached Biology News:Researchers identify ovarian cancer biomarkers 2Individual differences in a clock gene predict decline of performance during sleep deprivation 2Woven scaffolds could improve cartilage repair 2
... system is used for conventional PCR and ... MyCycler personal thermal cycler, which features a ... ml tubes or plates, programmable time, temperature, ... block modes of temperature control. The system ...
... Ciphergen's ProteinChip arrays have been ... from biological samples. A variety of ... of proteins according to their unique ... different spots, allowing side-by-side sample comparison, ...
The Freeze 'N Squeeze DNA gel extraction kit uses a quick freeze-and-thaw cycle and centrifugation to draw 50-23,000 bp DNA out of agarose gel slices. The kit includes materials for 100 preps....
The Econo gradient pump rack is a preassembled rack that is used to hold the components of the Econo gradient pump kits....
Biology Products: